Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Deciphering the cellular hierarchy of multiple myeloma uncovers a therapeutically exploitable EP300/TBX2 axis in LILRB4+ myeloma-initiating cells

View Full Paper
Ask AI
Bookmark
Share

Authors

SPShanshan PeiEZEnfan ZhangZCZhen Cai

Discussion

Loading...

Member takes

Overview

This research identifies TBX2-targeting strategies that enhance treatment responses in LILRB4+ myeloma-initiating cells, suggesting new therapeutic avenues.

Key Points

  • To reconstruct the cellular hierarchy of multiple myeloma and identify potential therapeutic targets.
  • Analyzed single-cell transcriptomic data from normal and multiple myeloma plasma cells.
  • Utilized flow cytometry for functional validation of identified myeloma populations.
  • Screened an epigenetic drug library for compounds affecting primitive myeloma populations.
  • Created an eight-stage developmental framework for plasma cells, revealing distinct myeloma subgroups.
  • Identified LILRB4 as a marker for high-stemness myeloma-initiating cells.
  • Demonstrated that TBX2 is a crucial factor for maintaining LILRB4 expression and viability against bortezomib.

Cite This Study

Pei et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236de7dhttps://doi.org/10.1182/blood-2025-2170
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1LILRB4 drives proinflammatory cytokine secretion in multiple myeloma to promote the immune-cell dysfunction via the generation of myeloid-derived suppressive cells2025
  2. 2LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma2024 · 12 citations
  3. 3Deciphering the role of EP300 in maintaining the enhancer landscape and lineage-specific epigenetic vulnerability in multiple myeloma2025
  4. 4The B2M–LILRB1 axis as a novel myeloid immune checkpoint and therapeutic target in multiple myeloma2025
  5. 5Revealing oncogenic enhancer regulation by epigenomic profiling of multiple myeloma and plasma cell leukemia patient samples2025